Discovery and preclinical research collaboration with Gilead Sciences to develop novel molecular glue degraders directed against cyclin-dependent kinase 2 (CDK2); Gilead holds exclusive option to license and commercialize globally

Targets: CDK2

Discontinued (1)

KT-474 — undisclosed · Sanofi stopped development of KT-474 following decision to advance KT-485/SAR447971

Biotech Distilled coverage (7)

2026-07-07 UPDATE: Kymera Therapeutics (KYMR) - They Hired the Person Who Built Dupixent
2026-06-30 UPDATE: Kymera Therapeutics (KYMR) - BVF Took the Trim I Flagged
2026-06-25 UPDATE: Kymera Therapeutics (KYMR) - The Binary Just Got Pulled Six Months Forward
2026-06-12 UPDATE: Kymera Therapeutics (KYMR) - The Japanese Bridge and a 12% Pop
2026-06-09 UPDATE: Kymera Therapeutics (KYMR) - The Sanofi Shield Cashes Another Check
2026-04-13 UPDATE: Kymera Therapeutics (KYMR) - Cashes a $45M Lottery Ticket and Greases the Regulatory Skids 🔒 Paid
2026-04-09 Kymera Therapeutics (KYMR) - Scientific Deep Dive on KT-621 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.